Clinical Trial Search

Primary: Change in Moderate-to-Vigorous Minutes of Physical Activity Per Week — 27.4; 83.0; 88.4; 54.5 Minutes of physical activity

Primary: Physical Activity Hours Per Day Measured Using a Body-worn Accelerometer at Baseline — 1.3; 1.6 h/day — p=0.037

Primary: Moderate to Vigorous Physical Activity (MVPA) — -0.7; 8.8 Average change in minutes per day — p=.023

Primary: Change in Physical Activity — 49.3; 15.1 minutes per week

Primary: Change in Physical Function (Part 1) — -15.0; -12.6 Seconds — p=0.35

Primary: Weight Change — -2.50; -0.51 percentage of body weight — p=0.008

Primary: Change in Automaticity Score. — 17 Participants

Primary: Moderate to Vigorous Physical Activity (MVPA) — -1.9; 3.4 average minutes per day — p=0.24

Primary: Clinically Significant Weight Loss — 39; 40 Participants — p=>0.05

Primary: Daily Steps Change From Baseline to Month 4; Main Effect, and 2- and 3-way Interactions — -343.5; -324.5; -859.9; 149.5 Average change in steps per day — p=.37

Primary: Proportion of Days a Minimum Activity of 7000 Steps or More is Achieved — 0.176; 0.254; 0.173; 0.350 Proportion of participant-days

Primary: Difference in Participant's Total Distance During 6-minute Walk — 458.775; 467.209; 452.355; 448.711 meters

Primary: Change in Physical Activity: Leisure Time Physical Activity Questionnaire for People With SCI (LTPAQ) — 212; 274; 393; NA Total LTPA min/week

Primary: Proportion of Days a Minimum Activity of 7000 Steps or More is Achieved During Intervention — 0.264; 0.319; 0.290; 0.384 Proportion of participant days

Primary: Balance — 26.7; 27.9; 34.7; 29.7 score on a scale

Primary: Part 1: Wheal Response-time Area Under the Curve (AUC) Over the 2 Hours Post-challenge Period Following Skin Challenge With Substance P- at Challenge Visit 1 (Day 1)…

Primary: Feasibility of DBS Collection as Measured by Number of Participants Who Provide DBS — 89; 29; 98; 24 Participants

Primary: Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06821497 — 3302; 3375; 3479; 11220 ng*hr/mL

Primary: VO2 Max — 16.6; 16.8; 15.7; 18.5 mL/kg/min — p=.82

Primary: Meaning Salience — 5.61 score on a scale

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 6; 7; 4; 9 Participants

Primary: REACH Session Feedback — 5.94 score on a scale

Primary: Intention to Talk to Doctor About Colorectal Cancer Screening — 4.14; 4.0; 3.59; 3.48 units on a scale

Primary: User Preference of the New Philips Respironics Positive Airway Pressure Application as Measured by the Attitudes Toward Use Questionnaire — 7.5; 7.9; 8.8 units on a scale

Primary: Change in Sedentary Behavior (Average Hour/Day) — -0.11; 0.05 Change in average daily hours — p=0.8

Primary: Weekly Moderate-Vigorous Physical Activity Minutes, Accelerometry — -21.4286; -53.9600; 19.6000; -38.6800 Minutes

Primary: Depression Symptoms Measured by Patient Health Questionnaire - 8 (PHQ-8) Score — 10.06; 9.85; 9.79; 9.17 score on a scale

Primary: Feasibility of Intervention Completion — 33 Participants

Primary: Percentage of Total Radiocarbon (14C) Excreted in Urine — 11.9; 20.7 Percentage of 14C in urine

Primary: Quantity of Physical Activity Measured Objectively — 177.9; 167.7; 185.9; 177.9 minutes per day